Login to Your Account

Vertex's CF sales steady for Q2 as firm seeks long-term growth

By Jennifer Boggs
Managing Editor

Wednesday, July 30, 2014
A phase II miss testing a combination of cystic fibrosis (CF) drugs in a heterozygous subset of patients with the F508del mutation slightly dented shares of Vertex Pharmaceuticals Inc. Wednesday morning, but the Boston-based biotech beat analyst estimates in the second quarter and looks well positioned to build out its CF franchise going forward.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription